After 35 years in the pharmaceutical industry, Barry Fishman shares his excitement about heading one of Canada’s leading licensed cannabis producers. He explains how his experience in the world of pharma helps him to steer ABcann towards global expansion and emphasizes the importance of product development in both adult-use and medical cannabis.
Barry, when we met in 2013 on behalf of Teva, you were advocating for higher generic penetration in Canada. Five years later, how have you come to support cannabis-based medicine?
"We identified a proven, scalable model in Harvest Medicine and are now in the process of expanding it to four additional locations over the next 12 months."
